Curis, Inc. and Genentech have initiated a Phase II trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC). The companies continue to work with clinical investigators to evaluate GDC-0449 in other diseases with Hedgehog-pathway mutations such as medulloblastoma, a childhood brain cancer and in BCCs in basal cell nevus (Gorlin) syndrome, a rare genetic disorder in which patients typica...